Marketing: Page 86
-
Could the Sanofi CEO's firing doom a $150 million inhaled insulin deal?
Viehbacher's boot could spell trouble for the partnership despite MannKind's assurances, according to one analyst.
By Sy Mukherjee • Nov. 4, 2014 -
RAND study: Biosimilars could save US $44 billion in 10 years
"However, the magnitude of savings will depend on a number of factors, including forthcoming decisions from the FDA," said the lead researcher.
By Sy Mukherjee • Nov. 4, 2014 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.
By BioPharma Dive staff -
One-fifth of all drug sales in 2020 could be for pricey, specialty orphan meds
An EvaluatePharma report predicts 19% of all Rx drug sales will stem from orphan drugs by 2020. But will payers resist increased spending for specialty drugs?
By Nicole Gray • Nov. 4, 2014 -
BMS gets heat from advocates over pricing plan for its hep C drug
BMS plans to offer Daklinza (daclatasvir) at heavily discounted prices in low-income countries, but critics say that middle-income countries are being unfairly left out.
By Nicole Gray • Nov. 4, 2014 -
Express Scripts gearing up to snub Gilead in favor of AbbVie hep C drug
Express Scripts' medical chief made it clear last week that the company's looking for an HCV treatment that is as effective as Gilead's Sovaldi (sofosbuvir)—but cheaper.
By Nicole Gray • Nov. 3, 2014 -
Deep Dive
ICYMI: 5 movies where biopharma goes horribly wrong
From deadly epidemics to mad scientists' experiments, these five horror/thriller flicks are sure to get your heart racing.
By Sy Mukherjee • Oct. 31, 2014 -
With Viehbacher gone, who will be the next Sanofi chief?
Every team needs a leader, and Sanofi's board of directors knows that. The question is: who can offer the type of pharmaceutical company leadership—and communication style—the board wants?
By Nicole Gray • Oct. 30, 2014 -
Deep Dive
Diving into the future of fixed-dose combos
From respiratory disease to HIV therapeutics, fixed-dose combinations are an important part of drug development. The regulatory hurdles are high—but so are the rewards.
By Nicole Gray • Oct. 30, 2014 -
Gilead shares fall on lower-than-expected Sovaldi sales
Sovaldi sales were down from $3.5 billion in Q2 to $2.8 billion in Q3. But Gilead's overall sales were up on a quarter-to-quarter basis.
By Nicole Gray • Oct. 29, 2014 -
UPDATED: Judge slashes Actos class action award from $9 billion to $36.8 million
Lilly and Takeda breathe a sigh of relief.
By Nicole Gray • Oct. 29, 2014 -
Cost-effectiveness: Treat prisoners with Sovaldi now, save money later
A new cost-effectiveness study shows that treating prisoners with Sovaldi can not only help offset long-term Medicaid costs, but prevent released prisoners from spreading hep C.
By Nicole Gray • Oct. 29, 2014 -
Pfizer posts weaker-than-expected Q3 while Sanofi CEO gets the boot
Global powerhouses Pfizer and Sanofi faced generic erosion, intense market competition, and government pricing pressures in Q3. It proved too much for Sanofi chief Chris Viehbacher.
By Nicole Gray • Oct. 29, 2014 -
Novartis smashes in Q3 as earnings soar 45%
Although much of Novartis' profit rise for Q3 2014 was attributable to the Idenix divestiture, the firm also enjoyed notable increases in generics and ophthalmology sales.
By Nicole Gray • Oct. 28, 2014 -
Determined Shire ratchets up 2014 forecast, again
A busted $55 billion deal with AbbVie? What busted $55 billion deal with AbbVie?
By Nicole Gray • Oct. 27, 2014 -
Merck beats Q3 forecasts, scores another Keytruda 'breakthrough'
Merck's revenues were down more than 20%, but some rigorous cost-cutting helped the company beat EPS expectations. And the FDA granted the historic Keytruda a second breakthrough designation.
By Sy Mukherjee • Oct. 27, 2014 -
BMS beats analyst expectations on strong cancer, RA drug sales
Cancer treatment Yervoy and rheumatoid arthritis drug Orencia both had impressive gains in sales.
By Sy Mukherjee • Oct. 24, 2014 -
Soliris sales drive Alexion's Q3 earnings beyond the loftiest expectations
Alexion Pharmaceuticals earned net income of $177.7 million in Q3 2014 versus $93.8 million in Q3 2013, an increase of 47%.
By Nicole Gray • Oct. 24, 2014 -
Lilly's Q3 profits drop sharply, hammered by patent expirations
Can the company's diabetes pipeline reverse the slump?
By Sy Mukherjee • Oct. 23, 2014 -
Biogen shares down as Tecfidera-treated patient dies from viral brain infection
While there were no cases of PML in Tecfidera clinical trials, it is a potential side effect of oral MS medications.
By Nicole Gray • Oct. 23, 2014 -
UK patients rally online to demand lower price for Roche's Kadcyla
At $145,000 per year, Roche's breast cancer drug Kadcyla is the most expensive oncologic in the UK.
By Nicole Gray • Oct. 23, 2014 -
Deep Dive
Best of BD: Biosimilars in China: The coming revolution
Despite a less rigorous approach to approving biosimilars, China has several approved follow-on biologics—and a growing number of biotechs want to develop biosimilars that meet global standards.
By Nicole Gray • Oct. 22, 2014 -
Glaxo, Abbott Q3 earnings best analyst expectations
Abbott's stellar Q3 report reflects a combination of growth across sectors. GSK was able to raise its outlook despite falling Advair sales and a hefty fine for bribery in China.
By Nicole Gray • Oct. 22, 2014 -
Mylan investor pulls $70 million as lethal injection controvery heats up
As the manufacturer of rocuronium bromide, the paralytic in lethal injection cocktails, Mylan is facing criticism and divestment.
By Nicole Gray • Oct. 22, 2014 -
Useful insights: Europe slow to embrace biosimilars of antibody-based drugs
After the EMA approved Hospira's Inflectra—a biosimilar of J&J's Remicade (infliximab)—Hospira launched an intensive marketing campaign. Here's an overview of what's happened since then.
By Nicole Gray • Oct. 21, 2014 -
PhRMA fights back, blames insurance companies for drug access woes
AccessBetterCoverage.org is choc-full of insurance facts. But its real message is that health insurers, and not pharma, are guilty of shifting drug costs onto consumers.
By Nicole Gray • Oct. 21, 2014
Previous
